- Home
- JAZZ
as 07-26-2024 4:00pm EST
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Upcoming Earnings Alert:
Get ready for potential market movements as Jazz Pharmaceuticals plc (Ireland) JAZZ prepares to release earnings report on 31 Jul 2024.
| Founded: | 2003 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN |
| Market Cap: | 6.9B | IPO Year: | 2007 |
| Target Price: | $185.47 | AVG Volume (30 days): | 531.6K |
| Analyst Decision: | Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 4.86 | EPS Growth: | N/A |
| 52 Week Low/High: | $99.06 - $146.70 | Next Earning Date: | 07-31-2024 |
| Revenue: | $3,843,375,000 | Revenue Growth: | 2.81% |
| Revenue Growth (this year): | 7.77% | Revenue Growth (next year): | 7.55% |
Stock Insider Trading Activity of Jazz Pharmaceuticals plc (Ireland) (JAZZ)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Carr Patricia | JAZZ | SVP, Chief Accounting Officer | Jun 7 '24 | Sell | $108.83 | 163 | $17,738.48 | 6,596 | SEC Form 4 |
| Patil Neena M | JAZZ | EVP & Chief Legal Officer | May 3 '24 | Sell | $109.65 | 5,000 | $548,250.00 | 36,629 | SEC Form 4 |
| Carr Patricia | JAZZ | SVP, Chief Accounting Officer | Mar 6 '24 | Sell | $120.85 | 1,236 | $149,370.60 | 9,064 | SEC Form 4 |
| Carr Patricia | JAZZ | SVP, Chief Accounting Officer | Mar 6 '24 | Sell | $117.51 | 700 | $82,257.00 | 8,364 | SEC Form 4 |
| Carr Patricia | JAZZ | SVP, Chief Accounting Officer | Mar 6 '24 | Sell | $116.98 | 1,768 | $206,820.64 | 6,596 | SEC Form 4 |
| Johnson Philip L | JAZZ | EVP & Chief Financial Officer | Mar 1 '24 | Buy | $119.65 | 12,000 | $1,435,800.00 | 27,932 | SEC Form 4 |
| Smith Mark Douglas | JAZZ | Director | Dec 4 '23 | Sell | $119.27 | 417 | $49,735.59 | 6,888 | SEC Form 4 |
| Cook Jennifer E. | JAZZ | Director | Dec 4 '23 | Sell | $119.27 | 417 | $49,735.59 | 6,888 | SEC Form 4 |
Latest Jazz Pharmaceuticals plc (Ireland) News
JAZZ Breaking Stock News: Dive into JAZZ Ticker-Specific Updates for Smart Investing
PR Newswire
a day ago
Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting
Zacks
a day ago
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Zacks
2 days ago
Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth
Argus Research
3 days ago
JAZZ: Raising target price to $114.00
Medical Device Network
4 days ago
Nanotechnology in medicine: Who are the leading public companies?
MT Newswires
4 days ago
Jazz Pharmaceuticals Reprices $2.7 Billion Outstanding Balance of Term Loan Facility
PR Newswire
5 days ago
Jazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026
PR Newswire
9 days ago
Jazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024
Compare JAZZ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JAZZ Jazz Pharmaceuticals plc (Ireland) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.